Ocugen(OCGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OCGN Ocugen

Trading 10-07 15:57:39 EDT

1.00

-0.04

-3.45%

High1.05	Low1.00	Vol4.85M
Open1.04	D1 Closing1.04	Amplitude4.81%
Mkt Cap339.90M	Tradable Cap328.90M	Total Shares338.52M
T/O4.95M	T/O Rate1.48%	Tradable Shares327.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OCGN","market":"US","secType":"STK","nameCN":"Ocugen","latestPrice":1.0041,"timestamp":1791403058244,"preClose":1.04,"halted":0,"volume":4845815,"delay":0,"changeRate":-0.03451923076923081,"floatShares":327561317,"shares":338516200,"eps":-0.255082,"marketStatus":"Trading","change":-0.0359,"latestTime":"10-07 15:57:39 EDT","open":1.04,"high":1.05,"low":1,"amount":4946052.1370195,"amplitude":0.048077,"askPrice":1.01,"askSize":69634,"bidPrice":1,"bidSize":268345,"shortable":3,"etf":0,"ttmEps":-0.255082,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791403200000},"marketStatusCode":2,"adr":0,"listingDate":1417582800000,"exchange":"NASDAQ","adjPreClose":1.04,"preHourTrading":{"tag":"盘前","latestPrice":1.05,"preClose":1.04,"latestTime":"09:24 EDT","volume":41219,"amount":43113.8126986,"timestamp":1791379443402,"change":0.01,"changeRate":0.009615,"amplitude":0.028846},"postHourTrading":{"tag":"盘后","latestPrice":1.04,"preClose":1.04,"latestTime":"19:54 EDT","volume":44906,"amount":46810.8969,"timestamp":1791330895780,"change":0,"changeRate":0,"amplitude":0.028846},"volumeRatio":0.914959,"impliedVol":1.1475,"impliedVolPercentile":0.4861},"requestUrl":"/m/hq/s/OCGN","defaultTab":"news","newsList":[{"id":"2673205371","title":"Ocugen Names Jolanda Crombach General Manager of European Affiliate","url":"https://stock-news.laohu8.com/highlight/detail?id=2673205371","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673205371?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:05","pubTimestamp":1791284705,"startTime":"0","endTime":"0","summary":"Ocugen names Jolanda Crombach general manager of European affiliateOcugen appointed Jolanda Crombach as general manager of its new European affiliate, headquartered in Amsterdam.Crombach previously se","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDL8rtfL4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","OCGN","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673053261","title":"Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate","url":"https://stock-news.laohu8.com/highlight/detail?id=2673053261","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673053261?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:02","pubTimestamp":1791284520,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA1LSNHM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCGN","BK4139","BK4563","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673705882","title":"Ocugen Reconvenes Special Shareholder Meeting, Adjourns Vote on Authorized Share Increase Proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2673705882","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673705882?lang=en_us&edition=fundamental","pubTime":"2026-10-06 18:01","pubTimestamp":1791280868,"startTime":"0","endTime":"0","summary":"Ocugen reconvenes special shareholder meeting, adjourns vote on authorized share increase proposalOcugen’s special stockholder meeting reconvened on Oct. 5, 2026, then adjourned again.Shareholders did","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDLbpjrKW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","OCGN","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673082625","title":"Ocugen Inc. Stock Rises Monday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2673082625","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673082625?lang=en_us&edition=fundamental","pubTime":"2026-10-06 05:29","pubTimestamp":1791235740,"startTime":"0","endTime":"0","summary":"DJ Ocugen Inc. Stock Rises Monday, Outperforms MarketThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Ocugen Inc.  rallied 1.96% to $1.04 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 0.66% to 7,773.95 and the Dow Jones Industrial Average  rising 0.18% to 51,267.90.This was the stock's second consecutive day of gains.Ocugen Inc. closed 61.83% short of its 52-week high of $2.73, which the company reached on March 17th.Trading volume  remained 635,867 below its 50-day average volume of 6.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled October 5, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672741676","title":"Ocugen Inc. Stock Rises Friday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2672741676","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672741676?lang=en_us&edition=fundamental","pubTime":"2026-10-03 05:29","pubTimestamp":1790976540,"startTime":"0","endTime":"0","summary":"DJ Ocugen Inc. Stock Rises Friday, Outperforms MarketThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Ocugen Inc.  advanced 2.00% to $1.02 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 0.73% to 7,722.72 and the Dow Jones Industrial Average  rising 0.49% to 51,176.96.The stock's rise snapped a two-day losing streak.Ocugen Inc. closed 62.57% below its 52-week high of $2.73, which the company reached on March 17th.Trading volume  remained 2.8 million below its 50-day average volume of 6.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled October 2, 2026.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672767943","title":"Ocugen Inc. Stock Falls Thursday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2672767943","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672767943?lang=en_us&edition=fundamental","pubTime":"2026-10-02 05:27","pubTimestamp":1790890020,"startTime":"0","endTime":"0","summary":"DJ Ocugen Inc. Stock Falls Thursday, Underperforms MarketThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Ocugen Inc.  slid 2.91% to $1.00 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 0.19% to 7,666.45 and the Dow Jones Industrial Average  rising 0.04% to 50,926.56.This was the stock's second consecutive day of losses.Ocugen Inc. closed 63.30% short of its 52-week high of $2.73, which the company achieved on March 17th.Trading volume  remained 1.0 million below its 50-day average volume of 6.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled October 1, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672799782","title":"Ocugen Inc. Stock Sheds 5.5%, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2672799782","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672799782?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:33","pubTimestamp":1790800380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Ocugen Inc. shed 5.5% to $1.03 on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.3% to 7,651.54 and Dow Jones Industrial Average falling 0.9% to 50,906.05.The stock's fall snapped a three-day winning streak.Ocugen Inc. closed 62.2% below its 52-week high of $2.73, which the company achieved on March 17th.Trading volume totaled 7.3 million, compared to the 50-day average of 6.1 million.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671207691","title":"Analyst Maintains Buy Rating on Ocugen as OCU400’s Early Revenue Pathway and Phase 3 Upside Support Unchanged $11 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2671207691","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671207691?lang=en_us&edition=fundamental","pubTime":"2026-09-30 21:16","pubTimestamp":1790774178,"startTime":"0","endTime":"0","summary":"Analyst Whitney Ijem from Canaccord Genuity maintained a Buy rating on Ocugen and keeping the price target at $11.00. Whitney Ijem has given his Bu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-rating-on-ocugen-as-ocu400s-early-revenue-pathway-and-phase-3-upside-support-unchanged-11-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-rating-on-ocugen-as-ocu400s-early-revenue-pathway-and-phase-3-upside-support-unchanged-11-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OCGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671619206","title":"Ocugen to Present 12-Month Phase 2 ArMaDa Trial Results for Ocu410 Gene Therapy in Geographic Atrophy at AAO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2671619206","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671619206?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:05","pubTimestamp":1790766359,"startTime":"0","endTime":"0","summary":"Ocugen to present 12-month Phase 2 ArMaDa trial results for OCU410 gene therapy in geographic atrophy at AAO 2026Ocugen flagged upcoming presentations of clinical trial results for its modifier gene t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL9lldjv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4139","IE00BN0W2W23.USD","SG9999014013.SGD","OCGN","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","NDAQ","IE00BN0W2V16.EUR","IE00BKPKM429.USD","BCDF","BK4568","IE00BQXX3C00.GBP","LU2210150020.SGD","BK4588","LU2210149790.SGD","BK4563","LU0314104364.USD","BK4112","IE00B64PRP62.GBP","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4585","SG9999014005.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671620147","title":"Ocugen to Participate in Upcoming Scientific Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2671620147","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671620147?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:02","pubTimestamp":1790766120,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Sept.  30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371762/0/en/ocugen-to-participate-in-upcoming-scientific-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","EIS","BK4139","OCGN","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671247594","title":"Ocugen Inc. Stock Rallies 5.8%, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2671247594","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671247594?lang=en_us&edition=fundamental","pubTime":"2026-09-30 04:33","pubTimestamp":1790713980,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Ocugen Inc. advanced 5.8% to $1.09 on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.2% to 7,670.84 and Dow Jones Industrial Average falling 0.3% to 51,349.92.This was the stock's third consecutive day of gains.Ocugen Inc. closed 60.0% below its 52-week high of $2.73, which the company reached on March 17th.Trading volume totaled 7.5 million, compared to the 50-day average of 6.0 million.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671168012","title":"Ocugen CEO Musunuri Moderates H.C. Wainwright Biotech on Tap Panel","url":"https://stock-news.laohu8.com/highlight/detail?id=2671168012","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671168012?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:04","pubTimestamp":1790679846,"startTime":"0","endTime":"0","summary":"Ocugen CEO Musunuri moderates H.C. Wainwright Biotech on Tap panelOcugen will join two October investor and industry conferences, with CEO Shankar Musunuri slated for panel discussions.Oct. 1, 2026: M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL40KhrK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","OCGN","LU2095319765.USD","SG9999014005.SGD","SG9999014021.USD","BCDF","IE00BGHQF748.EUR","NDAQ","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","BK4588","LU0314104364.USD","BK4585","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014039.USD","IE00BQXX3C00.GBP","BK4112","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127378311","title":"AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=1127378311","media":"Options & Short Sell","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127378311?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:44","pubTimestamp":1790642670,"startTime":"0","endTime":"0","summary":"","market":"other","thumbnail":"https://static.tigerbbs.com/92728b90ee3a8a92bf786a931a559165","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/92728b90ee3a8a92bf786a931a559165"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELIL","ELIS","AZN","GILD","VXRT","OCGN","MRNY","SNY","BNTX","LLY","GSK","MRNA","MRNX","LLII","VERU","VIR","MRK","SMMT","GSKH","NVAX","LLYX","PFE","ABT","JNJ","REGN","IBIO"],"isVideo":true,"video":{"duration":84,"video_url":"https://news-video-sg.skytigris.cn/videos/cdn/2802.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/2802.webp","audio_url":"https://static.tigerbbs.com/5b10203ee8e7af70c985cde92862eb24.mp3","isAI":true},"gpt_icon":0},{"id":"2670224864","title":"Ocugen Inc. Stock Rises Friday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2670224864","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670224864?lang=en_us&edition=fundamental","pubTime":"2026-09-26 05:27","pubTimestamp":1790371620,"startTime":"0","endTime":"0","summary":"DJ Ocugen Inc. Stock Rises Friday, Outperforms MarketThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Ocugen Inc.  rallied 2.00% to $1.02 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index  rising 0.51% to 7,743.41 and the Dow Jones Industrial Average  rising 0.93% to 51,828.62.Ocugen Inc. closed 62.57% short of its 52-week high of $2.73, which the company achieved on March 17th.Trading volume  eclipsed its 50-day average volume of 5.9 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 25, 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670447855","title":"Ocugen Shares Rise on Provisional Approval for Retinitis Pigmentosa Treatment in Bahamas","url":"https://stock-news.laohu8.com/highlight/detail?id=2670447855","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670447855?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:49","pubTimestamp":1790336940,"startTime":"0","endTime":"0","summary":"Shares of Ocugen ticked higher after its treatment for retinitis pigmentosa, or RP, a type of genetic eye disorder, got provisional approval and priority designation from regulators in the Bahamas.The stock was up 2.9% to $1.03 in premarket trading on Friday. At Thursday's market close, shares were down 26% year to date.Ocugen said it got the approval for OCU400 from the Larta Board, the regulatory agency responsible for reviewing and approving longevity and regenerative therapy programs in the Bahamas.The biotechnology company plans to treat the first RP patient with OCU400 within 90 days following full Larta approval.OCU400 is currently in Phase 3 development, targeting a broad RP indication from early- to late-stage disease and pediatric to adult patients.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ocugen Shares Rise on Provisional Approval for Retinitis Pigmentosa Treatment in Bahamas","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","BK4563","OCGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670423374","title":"Ocugen Wins Provisional Approval for Ocu400 in Bahamas Under LARTA Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2670423374","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670423374?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:02","pubTimestamp":1790334143,"startTime":"0","endTime":"0","summary":"Ocugen wins provisional approval for OCU400 in Bahamas under LARTA pathwayOcugen won provisional approval, priority designation in The Bahamas for OCU400 modifier gene therapy in retinitis pigmentosa.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nNDLbnh78m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","BK4563","IE00B64PRP62.GBP","SG9999014039.USD","LU2210150020.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","BK4139","IE00BKPKM429.USD","SG9999014005.SGD","BK4568","IE00BQXX3C00.GBP","LU0314104364.USD","SG9999014013.SGD","IE00BQXX3F31.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4112","OCGN","IE00BGHQF748.EUR","LU2095319765.USD","BK4588","IE00BN0W2W23.USD","BK4585","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670442338","title":"Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in the Bahamas to Provide Ocu400 to Patients for Treatment of Retinitis Pigmentosa","url":"https://stock-news.laohu8.com/highlight/detail?id=2670442338","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670442338?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:02","pubTimestamp":1790334120,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nTUA2LDD5D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCGN","BK4139","BK4563","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669343627","title":"Ocugen Inc. Stock Slips 3.8%, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2669343627","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669343627?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:34","pubTimestamp":1790195640,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Ocugen Inc. shed 3.8% to $1.00 on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.8% to 7,706.03 and Dow Jones Industrial Average falling 0.7% to 51,511.59.Ocugen Inc. closed 63.3% below its 52-week high of $2.73, which the company reached on March 17th.Trading volume totaled 12.1 million, compared to the 50-day average of 5.7 million.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669024231","title":"Ocugen Stockholders Meeting Draws Quorum with 160,214,431 Shares Represented","url":"https://stock-news.laohu8.com/highlight/detail?id=2669024231","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669024231?lang=en_us&edition=fundamental","pubTime":"2026-09-23 18:02","pubTimestamp":1790157735,"startTime":"0","endTime":"0","summary":"Ocugen stockholders meeting draws quorum with 160,214,431 shares representedOcugen held a special shareholder meeting on Sept. 21, 2026, focused on boosting authorized common shares by 250 million.Sha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL5BDx1Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCGN","BK4568","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669958121","title":"Ocugen Inc. Stock Falls Monday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2669958121","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669958121?lang=en_us&edition=fundamental","pubTime":"2026-09-22 05:28","pubTimestamp":1790026080,"startTime":"0","endTime":"0","summary":"DJ Ocugen Inc. Stock Falls Monday, Underperforms MarketThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Ocugen Inc.  slipped 2.83% to $1.03 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 1.49% to 7,764.70 and the Dow Jones Industrial Average  rising 0.71% to 52,048.83.The stock's fall snapped a three-day winning streak.Ocugen Inc. closed 62.20% below its 52-week high of $2.73, which the company achieved on March 17th.Trading volume  remained 1.6 million below its 50-day average volume of 5.7 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 21, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCGN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocugen.com","stockEarnings":[{"period":"1week","weight":-0.0459},{"period":"1month","weight":-0.2353},{"period":"3month","weight":-0.3067},{"period":"6month","weight":-0.4439},{"period":"1year","weight":-0.4286},{"period":"ytd","weight":-0.2296}],"compareEarnings":[{"period":"1week","weight":0.0195},{"period":"1month","weight":0.0116},{"period":"3month","weight":0.0452},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1425}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.078212},{"month":2,"riseRate":0.416667,"avgChangeRate":0.450959},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.023128},{"month":4,"riseRate":0.416667,"avgChangeRate":0.059316},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.059512},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.015086},{"month":7,"riseRate":0.5,"avgChangeRate":0.098423},{"month":8,"riseRate":0.416667,"avgChangeRate":0.062198},{"month":9,"riseRate":0.25,"avgChangeRate":-0.189485},{"month":10,"riseRate":0.416667,"avgChangeRate":0.007987},{"month":11,"riseRate":0.272727,"avgChangeRate":-0.198584},{"month":12,"riseRate":0.545455,"avgChangeRate":0.383124}],"exchange":"NASDAQ","name":"Ocugen","nameEN":"Ocugen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ocugen(OCGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ocugen(OCGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ocugen,OCGN,Ocugen股票,Ocugen股票老虎,Ocugen股票老虎国际,Ocugen行情,Ocugen股票行情,Ocugen股价,Ocugen股市,Ocugen股票价格,Ocugen股票交易,Ocugen股票购买,Ocugen股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ocugen(OCGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ocugen(OCGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}